PD-MitoQUANT Partner Spotlight – H. Lundbeck A/S

2020-04-10T10:39:26+01:00April 8th, 2020|News, Partner in the Spotlight|

With headquarters in Denmark, Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain diseases. For this purpose, Lundbeck is engaged in research, drug discovery development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas within psychiatry and neurology. Within PD-MitoQUANT, Lundbeck: is scientific co-leader as part of the PD-MitoQUANT Executive Team, evaluates a range of α-synuclein (α-αSyn) fibril species to select the most [...]

Meet Paula Scurfield, one of the PD-MitoQUANT PPI volunteers

2020-03-31T15:55:35+01:00March 31st, 2020|News|

The public, including patients, can and should be involved in all aspects of research, including study design, communication, and ethics. Patients bring unique knowledge and skills to projects, which can improve the quality of research. The Innovative Medicines Initiative encourages public and patient involvement (PPI) in all of its projects. PD-MitoQUANT is fortunate to have two people with Parkinson’s involved in the project through our patient advocacy partner Parkinson’s UK. Here, we meet Paula Scurfield. Paula was diagnosed with Parkinson’s [...]

Richard Campbell, Parkinson’s UK volunteer, blogs about his involvement in PD-MitoQUANT

2020-03-27T10:21:58+00:00March 25th, 2020|News|

PD-MitoQUANT is fortunate to have two people with Parkinson’s, Richard Campbell and Paula Scurfield, involved in the project through our patient advocacy partner Parkinson’s UK (www.parkinsons.org.uk). Recently, Richard wrote a blog entitled “Getting involved in an international research project on Parkinson’s”. "Paula Scurfield and I are part of the Parkinson’s UK Research Support Network and have joined the project as patient and public representatives. Our role is to advise on how information about the project is communicated, and how findings are shared [...]

PD-MitoQUANT study published in Scientific Reports by researchers at CNRS

2020-03-27T10:27:05+00:00March 20th, 2020|News|

Congratulations to our partners at the Centre National de la Recherche Scientifique (CNRS) for their March 17, 2020, open-access paper published in Scientific Reports. The paper entitled "The expression level of alpha-synuclein in different neuronal populations is the primary determinant of its prion-like seeding" was authored by Josquin Courte, Luc Bousset, Ysander Von Boxberg, Catherine Villard, Ronald Melki & Jean-Michel Peyrin. Find the entire list of PD-MitoQUANT acknowledged papers here: https://www.pdmitoquant.eu/publications/

New PD-MitoQUANT -acknowledged paper in Biophysical Journal

2020-03-11T12:00:21+00:00March 11th, 2020|News|

The open-access study titled: Differential Membrane Binding and Seeding of Distinct α-Synuclein Fibrillar Polymorphs published by the team consisting of AN Shrivastava, Luc Bousset, M Renner, V Redeker, J Savistchenko, A Triller and Ronald Melki was recently published in the Biophysical Journal on the 27th of January 2020. Congratulations to the whole team! See the growing list of PD-MitoQUANT-acknowledged publications here: https://www.pdmitoquant.eu/publications

PD-MitoQUANT publishes its second newsletter

2020-02-04T13:03:50+00:00February 3rd, 2020|News|

Happy New Year to all who are following the progress of PD-MitoQUANT. We are pleased to provide you with our latest project update. Please find our January 2020 newsletter for download here.  

Read the latest PD-MitoQUANT-acknowledged publication co-authored by our PIs at CNRS

2020-02-05T10:57:36+00:00January 20th, 2020|News|

Congratulations to all authors involved in the latest PD-MitoQUANT-acknowledged publication: Nolwen L. Rey, Luc Bousset, Sonia George, Zachary Madaj, Lindsay Meyerdirk, Emily Schulz, Jennifer A. Steiner, Ronald Melki and Patrik Brundin. PD-MitoQUANT PIs Luc Bousset and Ronald Melki are researchers at the Centre National de la Recherche Scientifique (CNRS). The open access paper entitled: α-Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb appears in Acta Neuropathologica Communications (2019) 7:221. The study was [...]

Interview with PI Dr Olga Corti, ICM

2020-01-20T16:32:41+00:00December 20th, 2019|News|

Olga Corti, PhD is a Research Director at the Institut du Cerveau et de la Moelle épinière (ICM) located in Paris, France. Olga is an expert in the functional analysis of protein products of Parkinson’s genes with a focus on mechanisms of mitochondrial quality control. We asked Olga some questions about her research and ICM’s role within PD-MitoQUANT. Within Parkinson’s research, which cell types and mechanisms are most interesting to you at the moment and why? Parkinson’s disease (PD) is [...]

PD-MitoQUANT PIs organise “pHysiopathology of Parkinson’s DisEase” (HOPE) 2020 conference at ICM, Paris

2019-12-12T14:37:50+00:00December 12th, 2019|News|

PD-MitoQUANT PIs Drs. Olga Corti, Stéphane Hunot (both based at the ICM) and Luc Bousset (Centre National de la Recherche Scientifique (CNRS)) are on the organizing committee of the 2nd "pHysiopathology of Parkinson's DisEase" (HOPE) conference taking place at the Institut du Cerveau et de la Moelle Epinière (ICM) in Paris from the 29th -31st January 2020.   Following the success of the first edition and the positive feedback from participants regarding the latest scientific advances and the integration of basic [...]

Highlights of PD-MitoQUANT Plenary Meeting, November 20/21, 2019

2019-12-11T11:33:53+00:00November 28th, 2019|News|

At the sunny coastal town of Herzeliya, Israel, over 35 participants from 8 countries across Europe and Israel gathered for the 2nd plenary meeting of the PD-MitoQUANT IMI Consortium to discuss their latest progress toward investigating the role of mitochondrial dysfunction in Parkinson’s. Hosted by Teva Pharmaceutical Industries, researchers from academia, industry and non-profit organizations presented their progress on developing cellular and animal models of Parkinson’s to investigate the impact of alpha-synuclein fibrils on mitochondrial function.   The emotional opening talks [...]

Go to Top